Imperial College London
Portrait Picture

Professor David S. Rueda

Faculty of Medicine, Department of Infectious Disease

Chair in Molecular and Cellular Biophysics
 
 
 
//

Contact

 

david.rueda Website

 
 
//

Location

 

6.12DLMS BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Masood:2023,
author = {Masood, M and Ding, Q and Cawte, AD and Rueda, DS and Grimm, SW and Yagüe, E and El-Bahrawy, M},
journal = {Cell Communication and Signaling},
title = {Genetic screening for anticancer genes highlights FBLN5 as a synthetic lethal partner of MYC},
url = {https://biosignaling.biomedcentral.com/articles/10.1186/s12964-023-01300-3},
volume = {21},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: When ectopically overexpressed, anticancer genes, such as TRAIL, PAR4 and ORCTL3, specifically destroy tumour cells without harming untransformed cells. Anticancer genes can not only serve as powerful tumour specific therapy tools but studying their mode of action can reveal mechanisms underlying the neoplastic transformation, sustenance and spread. Methods: Anticancer gene discovery is normally accidental. Here we describe a systematic, gain of function, forward genetic screen in mammalian cells starting with over 30,000 transcripts in order to isolate novel anticancer genes of human origin. FBLN5 was chosen, as a proof of principle, for mechanistic gene expression profiling, comparison pathways analyses and functional studies. Results: Sixteen novel anticancer genes were isolated; these included non-coding RNAs, protein-coding genes and novel transcripts, such as ZNF436-AS1, SMLR1, TMEFF2, LINC01529, HYAL2, NEIL2, FBLN5, YPEL4 and PHKA2-processed transcript. FBLN5 selectively caused inhibition of MYC in COS-7 (transformed) cells but not in CV-1 (normal) cells. MYC was identified as synthetic lethality partner of FBLN5 where MYC transformed CV-1 cells experienced cell death upon FBLN5 transfection, whereas FBLN5 lost cell death induction in MCF-7 cells upon MYC knockdown. Conclusions: Sixteen novel anticancer genes are present in human genome including FBLN5. MYC is a synthetic lethality partner of FBLN5.
AU  - Masood,M
AU  - Ding,Q
AU  - Cawte,AD
AU  - Rueda,DS
AU  - Grimm,SW
AU  - Yagüe,E
AU  - El-Bahrawy,M
PY  - 2023///
SN  - 1478-811X
TI  - Genetic screening for anticancer genes highlights FBLN5 as a synthetic lethal partner of MYC
T2  - Cell Communication and Signaling
UR  - https://biosignaling.biomedcentral.com/articles/10.1186/s12964-023-01300-3
UR  - http://hdl.handle.net/10044/1/106403
VL  - 21
ER  -
Download